Mostrar el registro sencillo del ítem
dc.contributor.author
Laham, Gustavo
dc.contributor.author
Martínez, Alfredo P.
dc.contributor.author
Rojas Gimenez, Wanda Mara
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Amaya, Lucas
dc.contributor.author
Abib, Anabel
dc.contributor.author
Echegoyen, Natalia
dc.contributor.author
Díaz, Carlos
dc.contributor.author
Lucero, Alicia
dc.contributor.author
Martelli, Antonella
dc.contributor.author
Videla, Cristina Mónica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Neukam, Karin
dc.contributor.author
Di Lello, Federico Alejandro
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.date.available
2024-02-05T13:12:04Z
dc.date.issued
2023-04
dc.identifier.citation
Laham, Gustavo; Martínez, Alfredo P.; Rojas Gimenez, Wanda Mara; Amaya, Lucas; Abib, Anabel; et al.; Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients; Springer; Journal of Nephrology; 36; 3; 4-2023; 861-872
dc.identifier.issn
1120-3625
dc.identifier.uri
http://hdl.handle.net/11336/225772
dc.description.abstract
Background and Aim: Dialysis patients are a high-risk population and have a reduced immune response to vaccination against SARS-CoV-2. The aim of this study was to assess the humoral response to homologous Gam-COVID-Vac (Sputnik V) and heterologous Sputnik V/mRNA-1273 (Moderna) vaccination in dialysis patients. The vaccination scheme depended on dose availability and the prioritization of risk populations as established by the Argentine Ministry of Health. Methods: Previous COVID-19 infection was determined in symptomatic patients. Binding IgG antibodies against the spike (S) receptor-binding domain (RBD) of SARS-CoV-2 (anti-S-RBD) concentration was assessed between 3 and 16 weeks after the boost dose. Anti-S-RBD antibodies were quantified using the Abbott Diagnostics SARS-CoV-2 IgG II Quant chemiluminescent microparticle immunoassay (CMIA) on an Architect i2000 SR and an Alinity I analyzer (Abbott Diagnostics, Abbott Park, Illinois, USA). To standardize the results to WHO binding antibody units (BAU), a correction factor for Abbott arbitrary units (AU) was applied where 1 BAU/mL equals 0.142 AU, as previously established by Abbott with the WHO international standard NIBSC 20–136. Following the manufacturer’s recommendations, samples were considered reactive for anti-S-RBD when titers were above 50 AU/mL (7.2 BAU/mL). An 80% protective effect (PROT-80) against symptomatic SARS-CoV-2 infection was assumed when anti-S-RBD titers were 506 BAU/ml or higher. Charlson Comorbidity Index (CCI) score was classified as mild = 1–2, moderate = 3–4, and severe ≥ 5. Side effects were evaluated until day 7 by patients´ self-reported questionnaire. Results: One hundred seven participants were enrolled [n = 84 homologous (SpV/SpV), nn 23 heterologous (SpV/Mod)]. Median (IQR) age was 64 (50–75) years old and 79 (73.8%) were male. Additionally, 19 (22.6%) of the SpV/SpV and 4 (17.4%) of the SpV/Mod group had a prior confirmed SARS-CoV-2 infection (p = 0.589). In the overall population, 103 patients reached seroconversion (96.3%). Anti-S-RBD IgG median titers (IQR) were higher in the heterologous [1222 (288–5680) BAU/mL] than in the homologous scheme [447 (100–1551) BAU/mL], p = 0.022. In a linear model adjusted for age, gender, days from first vaccination to boost dose and days from the boost dose to the anti-S-RBD IgG determination, previous SARS-COV-2 infection (B: 2062.2; CI95: 1231.8–2892.6; p < 0.001), and SpV/Mod vaccination scheme (B: 1294.6; CI95: 435.58–2147.6; p = 0.003) were independently associated with anti-S-RBD levels. Finally, a higher frequency of adverse effects was associated with the heterologous scheme, although they were well tolerated by all individuals. Conclusions: The present study provides evidence that the homologous SpV/SpV and heterologous SpV/Mod schemes showed good efficacy and safety in patients on chronic dialysis. These results could be useful for designing future vaccination strategies, especially aimed at this risk group.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Springer
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
DIALYSIS
dc.subject
GAM-COVID-VAC
dc.subject
HETEROLOGOUS SCHEME
dc.subject
MRNA-1273
dc.subject
SARS-COV-2
dc.subject
VACCINE
dc.subject
COVID-19
dc.subject.classification
Enfermedades Infecciosas
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Ciencias de la Salud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2024-01-25T14:09:59Z
dc.identifier.eissn
1121-8428
dc.journal.volume
36
dc.journal.number
3
dc.journal.pagination
861-872
dc.journal.pais
Alemania
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Berlín
dc.description.fil
Fil: Laham, Gustavo. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
dc.description.fil
Fil: Martínez, Alfredo P.. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
dc.description.fil
Fil: Rojas Gimenez, Wanda Mara. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
dc.description.fil
Fil: Amaya, Lucas. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
dc.description.fil
Fil: Abib, Anabel. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
dc.description.fil
Fil: Echegoyen, Natalia. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
dc.description.fil
Fil: Díaz, Carlos. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
dc.description.fil
Fil: Lucero, Alicia. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
dc.description.fil
Fil: Martelli, Antonella. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
dc.description.fil
Fil: Videla, Cristina Mónica. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
dc.description.fil
Fil: Neukam, Karin. Hospital Virgen del Rocío; España. Instituto de Biomedicina de Sevilla ; Consejo Superior de Investigaciones Cientificas ; Universidad de Sevilla;
dc.description.fil
Fil: Di Lello, Federico Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Virología; Argentina
dc.journal.title
Journal of Nephrology
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/10.1007/s40620-022-01446-2
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/s40620-022-01446-2
Archivos asociados